ASCO 2019
ASCO 2019 and the future of oncology/ Oncology/ Views & Analysis/ Views and analysis
ASCO 2019 round-up
ASCO 2019 and the future of oncology/ Oncology/ Video/ Views & Analysis/ Views and analysis
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial
mike.smith@pharmaphorum.com
ASCO 2019, kantar, Oncology
0 Comment
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis
ASCO 2019 – phase I data generates hope for the future
mike.hammerton@pharmaphorum.com
ASCO 2019, kantar, Oncology
0 Comment
ASCO 2019 Live coverage/ Oncology/ Views & Analysis/ Views and analysis
ASCO 2019 day five
mike.hammerton@pharmaphorum.com
ASCO 2019, kantar, Oncology
0 Comment
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis
ASCO 2019 – Enfortumab comes out fighting in bladder cancer
mike.hammerton@pharmaphorum.com
ASCO 2019, kantar, Oncology
0 Comment
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis
ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results
mike.hammerton@pharmaphorum.com
ASCO 2019, kantar, Oncology
0 Comment
ASCO 2019 and the future of oncology/ News/ News/ Oncology/ Top stories
Sanofi trumpets Darzalex rival isatuximab in refractory myeloma
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis
ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial
mike.smith@pharmaphorum.com
ASCO 2019, kantar, Oncology
0 Comment